Developing a care pathway for COPD patients with cancer
User-Centered Design of a COPD Care Pathway for Patients With Cancer
Wake Forest University Health Sciences · NCT05984680
This study is trying to create a better care plan for people with COPD who also have cancer, to make their treatment easier and address the challenges they face.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences (other) |
| Locations | 1 site (Winston-Salem, North Carolina) |
| Trial ID | NCT05984680 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a COPD care pathway specifically for patients with cancer, focusing on reducing treatment burdens and implementing essential components of COPD care. It seeks to identify and explain the challenges faced by patients and providers in managing COPD alongside cancer treatment. The study will gather insights from both patients and healthcare providers to characterize the treatment burdens and barriers to effective COPD care in community oncology clinics.
Who should consider this trial
Good fit: Ideal candidates include patients with a confirmed or suspected diagnosis of COPD who have received immune checkpoint inhibitors for cancer, as well as healthcare providers involved in the care of these patients.
Not a fit: Patients without a diagnosis of COPD or those not involved in cancer treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the management of COPD in cancer patients, leading to better health outcomes and reduced treatment burdens.
How similar studies have performed: While the specific approach of integrating COPD care pathways in oncology settings is relatively novel, similar studies have shown promise in addressing comorbidities in cancer care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* The participant has personal experience with medical management of COPD, defined as meeting at least one of the following criteria:
1. patient with clinical documentation of COPD (either as a confirmed or suspected diagnosis) and has received at least one dose of an immune checkpoint inhibitor for cancer or
2. provider who currently works at least part-time in a medical oncology clinic or
3. provider who works at least part-time to care for patients with known or suspected COPD.
A suspected diagnosis of COPD can be based on finding(s) by history, exam, or radiography (e.g., CT changes such as emphysema, bronchial wall thickening, or mucus plugging). A provider is defined as a physician, advanced practice provider, nurse, or respiratory therapist. Study team members are permitted to participate in the study if they meet eligibility criteria.
* Ability to understand and agree to participate on the study as described by the study information sheet.
* Capability of speaking or reading English.
Exclusion Criteria: Severe psychiatric symptoms; unusual social situation; or critical instability that would limit adherence to the study requirements, as determined by the study team.
Where this trial is running
Winston-Salem, North Carolina
- Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina, United States (RECRUITING)
Study contacts
- Principal investigator: Thomas Lycan, MD — Wake Forest Baptist Comprehensive Cancer Center
- Study coordinator: Sandra Norona
- Email: snorona@wakehealth.edu
- Phone: 336-716-0308
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Obstructive Pulmonary Disease, Lung Cancer, Head and Neck Cancer